The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
8 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,155,997 in first-year total cost, median $376,325.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-C (10)]2
- Special Emphasis Panel[ZRG1 ETTN-H (11)]2
- Special Emphasis Panel[ZRG1 ETTN-S (14)]2
- Special Emphasis Panel[ZRG1 ETTN-G (13)]1
- Special Emphasis Panel[ZRG1 NV-S (14)]1
Most frequent institutions
- AKELOS INC.1
- BRIXTON BIOSCIENCES, INC.1
- NEWVENTUREIQ, LLC1
- PARMEDICS, INC.1
- PASCALL SYSTEMS, INCORPORATED1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Developing Active Stimulation and Monitoring Technologies to Optimize Pain and Nociception Management During Regional Anesthesia, General Anesthesia, and Post-Operative Care1R42NS129395-01A1 | LE MAU, TUANPURDON, PATRICK L. | PASCALL SYSTEMS, INCORPORATED, MA | $474,416 | ZRG1 |
| 2023 | Targeting TLR4-lipid rafts to prevent postoperative pain1R42NS132622-01 | DOUGHERTY, PATRICK MKOGAN, YAKOV | RAFT PHARMACEUTICALS, LLC, CA | $414,835 | ZRG1 |
| 2023 | Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy1R41CA277875-01 | HAROUTOUNIAN, SIMON | NEWVENTUREIQ, LLC, MO | $403,240 | ZRG1 |
| 2023 | Protease-activated-receptor-2 antagonists for treatment of migraine pain1R41NS127637-01A1 | DEFEA, KATHRYN ANNEDUSSOR, GREGORY O | PARMEDICS, INC., CA | $310,351 | ZRG1 |
| 2022 | Optimization of an HCN1-Selective Inverse Agonist for the Treatment of Peripheral Neuropathic Pain1R42NS129370-01 | FOX, STEVEN R | AKELOS INC., NY | $349,409 | ZRG1 |
| 2022 | Injectable Ice Slurry Cooling Technology for Treatment of Postoperative Pain1R41AR080620-01A1 | SIDOTI, CHARLES | BRIXTON BIOSCIENCES, INC., MA | $252,130 | ZRG1 |
| 2020 | Development of a topical fixed-dose combination drug for peripheral neuropathic pain.1R41NS120354-01 | CALCUTT, NIGEL A.HANSEN, ANGELA | WINSANTOR, INC., CA | $699,491 | ZRG1 |
| 2020 | Novel non-narcotic analgesic for acute and chronic pain1R42NS119103-01A1 | BAZAN, HERNAN ABAZAN, NICOLAS G. | SOUTH RAMPART PHARMA, LLC, LA | $252,125 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.